Kezar Life Sciences Files 8-K

Ticker: KZR · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1645666

Kezar Life Sciences, INC. 8-K Filing Summary
FieldDetail
CompanyKezar Life Sciences, INC. (KZR)
Form Type8-K
Filed DateOct 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

Related Tickers: KZR

TL;DR

Kezar Life Sciences filed an 8-K on 10/10/24. Details TBD.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on October 10, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Kezar Life Sciences has made a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative news.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing?

The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as item information, but the specific details of these events are not provided in the text.

When was the earliest event reported in this filing?

The earliest event reported was on October 10, 2024.

What is Kezar Life Sciences, Inc.'s principal executive office address?

The principal executive offices are located at 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.

In which state was Kezar Life Sciences, Inc. incorporated?

Kezar Life Sciences, Inc. was incorporated in Delaware.

What is the IRS Employer Identification Number for Kezar Life Sciences, Inc.?

The IRS Employer Identification Number is 47-3366145.

Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-10 08:42:12

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 10, 2024, Kezar Life Sciences, Inc. (the "Company") issued a press release confirming the receipt of an unsolicited and non-binding proposal from Concentra Biosciences, LLC to acquire all of the outstanding shares of common stock of the Company . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated October 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: October 10, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing